Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-label Prospective Cohort Study of the Efficacy and Safety of the Inclusion of Longidaze in the Prevention and Treatment of Post-inflammatory Pulmonary Fibrosis and Interstitial Lung Diseases Caused by COVID-19.

NCT04645368 is registered in ClinicalTrials.gov with NPO Petrovax as lead sponsor.

NCT NCT04645368
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04645368 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-label Prospective Cohort Study of the Efficacy and Safety of the Inclusion of Longidaze in the Prevention and Treatment of Post-inflammatory Pulmonary Fibrosis and Interstitial Lung Diseases Caused by COVID-19.
Lead sponsor
NPO Petrovax
Phase
Observational
Overall status
Completed
Start date
July 1, 2020
Completion date
April 20, 2022
Enrollment
160 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

fibroses, pulmonary